Cellgram CKD(Cellgram CKD) - _专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

Allogeneic bone marrow-derived mesenchymal stem cell therapy

靶点-

作用机制

细胞凋亡抑制剂、细胞替代物

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

慢性肾病勃起功能障碍

原研机构

Pharmicell Co., Ltd.

在研机构-

非在研机构

Pharmicell Co., Ltd.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Cellgram CKD 相关的临床试验

NCT05042206 / Completed临床1期

An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease.
The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.

开始日期2021-11-24

申办/合作机构

Pharmicell Co., Ltd.

NCT02344849 / Completed临床1期

An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.

This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

开始日期2015-07-01

申办/合作机构

Pharmicell Co., Ltd.

NCT01716481 / Unknown status临床3期IIT

Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study

The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.

开始日期2012-11-01

申办/合作机构